Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Trajectories of Childhood Adversity and Type 1 Diabetes: A Nationwide Study of One Million Children

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Comparison of Continuous Glucose Monitoring Accuracy Between Abdominal and Upper Arm Insertion Sites

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Preserved glucose response to low-dose glucagon after exercise in insulin pump-treated individuals with type 1 diabetes: a randomised crossover study

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  • Leah M Wilson
  • Peter G Jacobs
  • Katrina L Ramsey
  • Navid Resalat
  • Ravi Reddy
  • Deborah Branigan
  • Joseph Leitschuh
  • Virginia Gabo
  • Florian Guillot
  • Brian Senf
  • Joseph El Youssef
  • Isabelle Isa Kristin Steineck
  • Nichole S Tyler
  • Jessica R Castle
View graph of relations

OBJECTIVE: To assess the efficacy and feasibility of a dual-hormone (DH) closed-loop system with insulin and a novel liquid stable glucagon formulation compared with an insulin-only closed-loop system and a predictive low glucose suspend (PLGS) system.

RESEARCH DESIGN AND METHODS: In a 76-h, randomized, crossover, outpatient study, 23 participants with type 1 diabetes used three modes of the Oregon Artificial Pancreas system: 1) dual-hormone (DH) closed-loop control, 2) insulin-only single-hormone (SH) closed-loop control, and 3) PLGS system. The primary end point was percentage time in hypoglycemia (<70 mg/dL) from the start of in-clinic aerobic exercise (45 min at 60% VO2max) to 4 h after.

RESULTS: DH reduced hypoglycemia compared with SH during and after exercise (DH 0.0% [interquartile range 0.0-4.2], SH 8.3% [0.0-12.5], P = 0.025). There was an increased time in hyperglycemia (>180 mg/dL) during and after exercise for DH versus SH (20.8% DH vs. 6.3% SH, P = 0.038). Mean glucose during the entire study duration was DH, 159.2; SH, 151.6; and PLGS, 163.6 mg/dL. Across the entire study duration, DH resulted in 7.5% more time in target range (70-180 mg/dL) compared with the PLGS system (71.0% vs. 63.4%, P = 0.044). For the entire study duration, DH had 28.2% time in hyperglycemia vs. 25.1% for SH (P = 0.044) and 34.7% for PLGS (P = 0.140). Four participants experienced nausea related to glucagon, leading three to withdraw from the study.

CONCLUSIONS: The glucagon formulation demonstrated feasibility in a closed-loop system. The DH system reduced hypoglycemia during and after exercise, with some increase in hyperglycemia.

Original languageEnglish
JournalDiabetes Care
Issue number11
Pages (from-to)2721-2729
Number of pages9
Publication statusPublished - Nov 2020

ID: 61376820